Biomerica's inFoods® IBS Therapy Shows Strong Real-World Efficacy
Event summary
- Nearly 60% of IBS patients achieved clinically meaningful pain reduction, and 68% saw bloating reduction with inFoods® IBS Therapy in a real-world study.
- CMS established a $300 national Medicare payment rate for the inFoods® IBS test, effective January 1, 2026.
- Henry Schein partnership provides access to 400 medical field sales and tele-sales representatives targeting primary care and gastroenterology practices.
- American Medical Association approved a unique CPT® PLA code for inFoods® IBS, effective October 1, 2025.
The big picture
Biomerica's real-world data for inFoods® IBS Therapy validates its clinical utility, aligning with FDA-recognized endpoints from controlled trials. The therapy addresses a significant unmet need in the $30 billion IBS market, offering a non-pharmacologic, precision-based approach. The CMS payment rate and Henry Schein partnership position Biomerica to accelerate commercialization and market penetration.
What we're watching
- Commercialization Pace
- How quickly Biomerica can scale the inFoods® IBS Therapy adoption through the Henry Schein partnership and CMS reimbursement.
- Insurance Coverage
- Whether private insurers will follow CMS's lead in covering the inFoods® IBS test, expanding market access.
- Clinical Validation
- The consistency of real-world outcomes compared to controlled trial results as more patients are treated.
Related topics